Cameron Santoro

Positive results of sintilimab, IBI305, and hepatic arterial infusion chemotherapy (HAIC) treatment showed shrinking tumors and previously converting inoperable hepatocellular carcinoma (HCC) to resectable HCC with manageable adverse effects.

Here are the top 5 biosimilar articles for the week of April 8, 2024.

Intellectual property attorney Ha Kung Wong, JD, describes the patent dance and how it is designed to streamline information exchange while avoiding unnecessary lawsuits by allowing early assessment of patent infringement and validity.

Here are the top 5 biosimilar articles for the week of April 1, 2024.

Here are the top 5 biosimilar articles for the week of March 25, 2024.

Switching to the biosimilar version of tocilizumab (BAT1806/BIIB800) showed similar effectiveness, safety, and tolerability compared with the original drug for patients with rheumatoid arthritis (RA) who had an inadequate response to methotrexate.

Germany-based biosimilar manufacturer STADA Arzneimittel reports strong financial performance in 2023 with double digit sales growth and billions in profits. The CEO credits the company’s success on their strong company culture and focus for innovation.

Ha Kung Wong, JD, an intellectual property attorney, discusses lawsuits by drug companies aimed at delaying competition from biosimilars, but the effectiveness of these lawsuits in hindering biosimilar access remains uncertain.

Here are the top 5 biosimilar articles for the week of March 18, 2024.

A large-scale study found that Omnitrope, a biosimilar growth hormone, is effective and well-tolerated in treating various growth disorders in children.

Here are the top 5 biosimilar articles for the week of March 11, 2024.

A study found combining trastuzumab biosimilar HLX02, pertuzumab, and chemotherapy was effective and safe for patients with HER2-positive metastatic breast cancer who progressed after prior trastuzumab therapy.

Intellectual property attorney, Ha Kung Wong, JD, discusses concerns about "bad patents" hindering biosimilar access, but assures that the FDA and United States Patent and Trademark Office are working to improve the system.

Here are the top 5 biosimilar articles for the week of March 4, 2024.

A Chinese phase 3 trial found biosimilar QL1207 to be as effective and safe as reference aflibercept (Eylea) for the treatment of neovascular age-related macular degeneration (nAMD).

Here are the top 5 articles for the week of February 26, 2024.

Ha Kung Wong, JD, examines proposed patent law changes that could significantly impact the biosimilars sector, including limitations on asserted patents, elimination of interchangeability requirements, and heightened oversight of pharmacy benefit managers.

Here are the top 5 biosimilar articles for the week of February 19, 2024.

A large Chinese study found that HanliKang (HLX01), a biosimilar rituximab, had similar overall survival and progression-free survival rates to the reference product (Rituxan) in patients with diffuse large B-cell lymphoma (DLBCL).

Here are the top 5 biosimilar articles for the week of February 12, 2024.

Similar efficacy, safety, pharmacokinetics, and immunogenicity were found when comparing Stelara, originator ustekinumab, and CT-P43, an ustekinumab biosimilar candidate, in patients with moderate to severe plaque psoriasis.

In an interview with Ha Kung Wong, JD, he addresses the patent legal system biosimilars are required to undergo and how this helps resolve patent disputes early in the development process.

Here are the top 5 biosimilar articles for the week of February 5, 2024.

Etanercept biosimilar SB4 is just as effective as the originator drug (Enbrel) in treating Australian patients with rheumatoid arthritis (RA), leading to significant cost savings.

Here are the top 5 biosimilar articles for the week of January 29, 2024.

A study found SB15, an aflibercept biosimilar, is just as effective as its reference drug Eylea, the current standard treatment for neovascular age-related macular degeneration (nAMD), a condition that causes vision loss.

A 10-year analysis in Poland found that the introduction of biosimilar drugs significantly increased access to biologic therapies and Janus kinase (JAK) inhibitors for patients with rheumatic musculoskeletal diseases (RMDs), while also reducing treatment costs.

Here are the top 5 biosimilar articles for the week of January 22, 2024.

A combined analysis of 3 studies found that the drug MB02 is comparable to reference bevacizumab (Avastin) in terms of its pharmacokinetics, safety, and immunogenicity.

Biosimilar uptake was greater in Medicare Advantage plans when compared with traditional Medicare plans.